A new study published this month in the Journal of the American Medical Association (JAMA) confirmed what most healthcare stakeholders already believed: the United States spends more on healthcare than any other nation, yet it sees poorer results.

But the study named names. The biggest culprits contributing high-cost, low-value healthcare? Brand-name pharmaceuticals, defensive medicine and administration.

Generics make up only 30% of drug sales; expensive brand-name drugs continue to be offered first even when effective generics are available. American providers order more (and more expensive) tests than do peers in other developed nations. And spiraling administration costs are more likely to bleed US payers than are costs associated with clinical inefficiencies.

Get the full analysis here from ABC News.